Press Release Details

Cerus Corportation Names Vice President of Marketing

February, 20 2001
Cerus Corporation (Nasdaq: CERS) today announced the appointment of James J. Vaughn, R.Ph., to the position of vice president, Marketing. Mr. Vaughn, a proven sales and marketing executive, joins Cerus with over 14 years of experience in the pharmaceutical industry.

"We are pleased to have an executive of Jim's caliber join the Cerus management team," said Stephen T. Isaacs, president and chief executive officer of Cerus. "As we progress toward commercialization with our Intercept products, Jim will focus on the launch and adoption of these products as well as provide valuable insight toward sustaining future growth of the company through an expanded pipeline. His global experience and strengths launching, selling and marketing pharmaceutical products will complement the activities of Baxter Healthcare Corporation, which has primary responsibility for the sales and marketing of the Intercept Blood Systems."

Vaughn, 38, joins Cerus from Pharmacia where he held several sales and marketing management positions and was most recently senior director, Global Cox-2 Oncology Marketing for Pharmacia. In this position, he led the commercial development of the cox-2 platform in oncology, including Celebrex, (celecoxib). Vaughn also held positions as director, Marketing European Oncology and associate director, Global New Business Development, Oncology, during his tenure at Pharmacia. Prior to Pharmacia, he held various sales, managed care and sales management positions at Immunex, a Seattle-based biotechnology company. Mr. Vaughn also spent nine years in various positions at Lederle Laboratories. He holds a B.S. in Pharmacy from Creighton University, Omaha and an M.B.A. from Kellogg School of Business, Northwestern University.


Cerus Corporation is developing medical systems and therapeutics based on the company's proprietary Helinx technology for inactivating disease-causing agents. Helinx is designed to target and lock DNA or RNA, and has the ability to prevent the replication of viruses, bacteria and other pathogens and to control cellular proliferation. The company's most advanced programs are focused on systems to enhance the safety of the world's blood supply. These Intercept Blood Systems, based on the Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based biopharmaceutical company, in collaboration with its development and commercialization partner Baxter Healthcare Corporation, has submitted a CE Mark Application for marketing approval of the Intercept Platelet System in Europe. In addition, the company is conducting clinical trials of the Intercept Blood Systems in the United States: a Phase III trial for platelets, for which enrollment is complete, a Phase III trial for plasma and a Phase Ic trial for red blood cells.

Helinx is a trademark of Cerus Corporation

Intercept Blood System, Intercept Platelet System, Intercept Plasma System and Intercept Red Blood Cell System are trademarks of Baxter International, Inc. (NYSE: BAX)

Statements in this news release regarding commercialization, regulatory process and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the uncertainty of the timing and results of any clinical trials, action by regulatory authorities, the uncertainty of market acceptance of any products or competitive conditions, the uncertainty of future financing and other factors discussed in the company's 1999 Annual Report on Form 10-K and Cerus' Prospectus dated November 1, 2000.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600